The Independent Director of Taysha Gene Therapies, Inc. (NASDAQ:TSHA), Paul Manning, Just Bought A Few More Shares

Potential Taysha Gene Therapies, Inc. (NASDAQ:TSHA) shareholders may wish to note that the Independent Director, Paul Manning, recently bought US$251k worth of stock, paying US$12.54 for each share. However, it only increased shareholding by a small percentage, and it wasn't a huge purchase by absolute value, either.

See our latest analysis for Taysha Gene Therapies

The Last 12 Months Of Insider Transactions At Taysha Gene Therapies

In fact, the recent purchase by Independent Director Paul Manning was not their only acquisition of Taysha Gene Therapies shares this year. They previously made an even bigger purchase of US$252k worth of shares at a price of US$20.98 per share. So it's clear an insider wanted to buy, even at a higher price than the current share price (being US$12.53). It's very possible they regret the purchase, but it's more likely they are bullish about the company. In our view, the price an insider pays for shares is very important. It is generally more encouraging if they paid above the current price, as it suggests they saw value, even at higher levels.

Taysha Gene Therapies insiders may have bought shares in the last year, but they didn't sell any. The average buy price was around US$15.94. These transactions suggest that insiders have considered the current price attractive. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Insider Ownership

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Taysha Gene Therapies insiders own 42% of the company, currently worth about US$202m based on the recent share price. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.

So What Do The Taysha Gene Therapies Insider Transactions Indicate?

It's certainly positive to see the recent insider purchase. And an analysis of the transactions over the last year also gives us confidence. But we don't feel the same about the fact the company is making losses. Once you factor in the high insider ownership, it certainly seems like insiders are positive about Taysha Gene Therapies. One for the watchlist, at least! So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Our analysis shows 3 warning signs for Taysha Gene Therapies (1 shouldn't be ignored!) and we strongly recommend you look at them before investing.

But note: Taysha Gene Therapies may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.